Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Apr. 27, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is Defendants’ Motion for Leave to Amend Invalidity Contentions (“Motion to Amend”), Dkt. No. 303. The Motion to Amend is GRANTED, and the parties are directed to meet and confer regarding appropriate fact discovery related to the subject matter of the motion, as discussed below. BACKGROUND The defendant pharmaceutical companies are seeking approval by the Food and Drug Administration to sell a generic version of Restasis, an ophthalmic product sold by plaintiff Allergan, Inc.